Category: C.R. Bard
The CEOs of medical device companies Boston Scientific and C.R. Bard are cool on the consolidation trend in medtech, saying they don't see the need for mega-deals to grow their businesses.
C.R. Bard reports a 3rd-quarter earnings gain of nearly 50% and raises its guidance for the rest of the year, sending share prices up this morning on Wall Street.
C.R. Bard (NYSE:BCR) shares are up more than 3% this morning on Wall Street after the medical device company reported that its 3rd-quarter earnings rose 47.0% compared with the same period last year.
Here's a look at some of the top legal news stories for medical device companies this week: Supreme Court passes on Mirowski-Medtronic patent case; Medtronic can't shake shareholders lawsuit over Infuse; FDA strikes out again in Prevor drug-or-device case; Ex-Bard, BD engineer gets 18 months for stealing trade secrets; Appeals court: Fujifilm Medical executive wasn't fired for not being Japanese
A former engineer for Becton, Dickinson & Co. and C.R. Bard who confessed to stealing trade secrets concerning an injector pen is sentenced to 18 months in prison.
Here's a look at some of the top regulatory stories for medical device companies this week: 3rd FDA panel vote barely favors Boston Scientific's Watchman anti-stroke device; Medtronic launches Verify incontinence device in the U.S.; FDA OKs Integra Lifesciences Puerto Rico plant; FDA approves Bard's Lutonix DEB
Here's a look at some of the top legal news stories for medical device companies this week: Shareholder sues Medtronic over plan to cover execs' $58m tax tab; Report: Bard's mesh settlement is worth $21m; Covidien's Ev3 logs a pair of legal wins over Appriva, whistleblower; BD loses bid to overturn $114m antitrust loss to Retractable Technologies; Ex-Oriole DeCinces fights insider trading charges
The FDA grants pre-market approval for C.R. Bard's Lutonix drug-eluting balloon for treating peripheral artery disease.
C.R. Bard (NYSE:BCR) said today that the FDA granted pre-market approval for its Lutonix drug-eluting balloon for treating peripheral artery disease, well ahead of the company's expectation for approval early next year.